Abstract:Abstract Diffuse large B cell lymphoma (DLBCL) is an aggressive blood cancer known for its rapid progression and high incidence. The growing use of immunohistochemistry (IHC) has significantly contributed to the detailed cell characterization, thereby playing a crucial role in guiding treatment strategies for DLBCL. In this study, we developed an AI-based image analysis approach for assessing PD-L1 expression in DLBCL patients. PD-L1 expression represents as a major biomarker for screening patients who can benefit from targeted immunotherapy interventions. In particular, we performed large-scale cell annotations in IHC slides, encompassing over 5101 tissue regions and 146,439 live cells. Extensive experiments in primary and validation cohorts demonstrated the defined quantitative rule helped overcome the difficulty of identifying specific cell types. In assessing data obtained from fine needle biopsies, experiments revealed that there was a higher level of agreement in the quantitative results between Artificial Intelligence (AI) algorithms and pathologists, as well as among pathologists themselves, in comparison to the data obtained from surgical specimens. We highlight that the AI-enabled analytics enhance the objectivity and interpretability of PD-L1 quantification to improve the targeted immunotherapy development in DLBCL patients.

What problem does this paper attempt to address?

The paper aims to address the issue of PD-L1 expression assessment in Diffuse Large B-Cell Lymphoma (DLBCL). Specifically, the study developed an artificial intelligence-based image analysis method to evaluate PD-L1 expression in DLBCL patients. PD-L1 expression, as an important biomarker for selecting patients who may benefit from targeted immunotherapy, is significant in guiding treatment strategies for DLBCL. The main contributions of the study include: 1. Developed a PD-L1 expression scoring framework for lymphoma that can accurately quantify the well-known Tumor Proportion Score (TPS). 2. Proposed a digital quantification rule for PD-L1, addressing the challenge of screening tumor cells in immunohistochemical sections of DLBCL. 3. Constructed primary and validation cohorts with large-scale available annotations, covering more than 5,101 tissue regions and 146,439 viable cells. Through these methods, the researchers demonstrated the practicality of quantifying complex PD-L1 expression and highlighted its potential in advancing targeted immunotherapy for DLBCL patients. Additionally, the study showed a high level of consistency between the results of the artificial intelligence algorithm and pathologists, thereby enhancing the objectivity and interpretability of PD-L1 quantification.

Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma